share_log

Novavax | DEFA14A: Others

Novavax | DEFA14A: Others

诺瓦瓦克斯医药 | DEFA14A：其他
美股sec公告 ·  06/05 06:06
Moomoo AI 已提取核心信息
Novavax, Inc. has filed Amendment No. 1 to its Definitive Proxy Statement with the U.S. Securities and Exchange Commission on April 29, 2024, in preparation for its 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. This amendment specifically addresses and clarifies an immaterial aspect of the Amended and Restated 2015 Stock Incentive Plan related to 'Proposal 3 – Amendment and Restatement of the 2015 Stock Plan.' The amendment introduces new compensation limits for non-employee directors, setting a cap of $1,500,000 for the chairman and $1,000,000 for other non-employee directors, with an exception for the year in which a non-employee director begins their service on the Board. The amendment also removes the individual limits on awards granted under the 2015 Stock Plan, which previously restricted the number of shares for stock options, stock appreciation rights (SARs), and other stock awards. This filing does not affect any other items or information presented in the original 2024 Definitive Proxy Statement and should be read in conjunction with it.
Novavax, Inc. has filed Amendment No. 1 to its Definitive Proxy Statement with the U.S. Securities and Exchange Commission on April 29, 2024, in preparation for its 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. This amendment specifically addresses and clarifies an immaterial aspect of the Amended and Restated 2015 Stock Incentive Plan related to 'Proposal 3 – Amendment and Restatement of the 2015 Stock Plan.' The amendment introduces new compensation limits for non-employee directors, setting a cap of $1,500,000 for the chairman and $1,000,000 for other non-employee directors, with an exception for the year in which a non-employee director begins their service on the Board. The amendment also removes the individual limits on awards granted under the 2015 Stock Plan, which previously restricted the number of shares for stock options, stock appreciation rights (SARs), and other stock awards. This filing does not affect any other items or information presented in the original 2024 Definitive Proxy Statement and should be read in conjunction with it.
2024年4月29日，Novavax公司向美国证券交易委员会递交了第1修订版的《确定性代理声明书》，以准备2024年6月13日的股东年会。此修订版明确了2015年股票激励计划修订案中一个不重要的方面，与“提案3-修订和重申2015年股票计划”有关。修订版为非雇员董事引入了新的薪酬限制，主席限额为150万美元，其他非雇员董事限额为100万美元，但对于非雇员董事开始任职的年度除外。修订版还取消了2015年股票计划下奖励的个人限制，这些限制以前限制了股票期权、股票增值权（SARs）和其他股票奖励的股票数。这一递交不会影响原定2024年确定性代理声明中提出的任何其他事项或信息，应与原文件一起阅读。
2024年4月29日，Novavax公司向美国证券交易委员会递交了第1修订版的《确定性代理声明书》，以准备2024年6月13日的股东年会。此修订版明确了2015年股票激励计划修订案中一个不重要的方面，与“提案3-修订和重申2015年股票计划”有关。修订版为非雇员董事引入了新的薪酬限制，主席限额为150万美元，其他非雇员董事限额为100万美元，但对于非雇员董事开始任职的年度除外。修订版还取消了2015年股票计划下奖励的个人限制，这些限制以前限制了股票期权、股票增值权（SARs）和其他股票奖励的股票数。这一递交不会影响原定2024年确定性代理声明中提出的任何其他事项或信息，应与原文件一起阅读。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息